turn. One solution to this problem has been the development of a injectable extended-release naltrexone (XR-NTX) which provides a sustained release of medication for up to four weeks ... Minneapolis VA Medical Center…
novel formulation of extended-release (ER) methylphenidate hydrochloride that utilizes multiple layers of coatings on beads for encapsulation into hard gelatin capsule shells (Aptensio®, MPH-MLR) was evaluated to…
dyslipidemia, has shown problems with undesirable side effects and safety issues. Wax-matrix, extended-release niacin (WMER) and inositol hexanicotinate (IHN) have both been formulated to increase patient tolerability…
Formulation of Gliclazide in the form of extended-release tablet in 30 and 60 mg dosage forms was performed using hypromellose (HPMC K4M) as a retarding agent. Drug-release profiles ... used to predict the HPMC K4M…
days. In the present study, we evaluated the preclinical pharmacokinetic profile of new extended-release tablets of BNZ aiming the reduction of the frequency of administration of the drug ... immediate-release tablet…
ease of administration. The main objective of the present research was to develop extended-release capsule formulations containing histone deacetylase inhibitor (HDACI) sulforaphane-encapsulated albumin microspheres…
Extended-release delivery of BCS class II and III compounds is desirable in order to decrease dosing frequency and potential adverse effects. Maintaining an extended-release profile of the drug ... feasibility of a…
Tramadol hydrochloride 100 mg extended-release tablets is available as the registered trademark, Tramal® retard in Thailand to reduce a dosing frequency for the treatment of moderate to severe pain ... Government…
Oral drug administration remains the most convenient and preferred route of delivery. However, oral extended-release drug products have not yet reached their full potential in the clinic ... biodegradable polymers. The…
daily formulation. Therefore, these studies evaluated the pharmacokinetic profile of a new 30-mg Extended-Release Nifedipine Tablets in Mexican population. The formulation [ANHITEN-A®] was manufactured by Ultra…
United States. There exists a relative paucity of evidence in guiding management of acetaminophen Extended-Release ingestions compared to immediate-release ingestions. Many case reports involving Extended-Release…
opioid formulation intended to deter abuse, comprising capsules filled with pellets of extended-release oxycodone hydrochloride, an opioid, surrounding sequestered naltrexone hydrochloride, an opioid antagonist. This…
symptom control and relapse prevention. This study assessed bioequivalence and safety of paliperidone palmitate Extended-Release (ER) Injectable suspension (Paliris LA®) (Test(T)) manufactured by Sun Pharmaceuticals…
Aptensio XR® is an Extended-Release (ER) Methylphenidate (MPH) capsule drug product, approved for use in patients 6 years and older. Absorption of Aptensio XR® in children has been characterized
Objectives: Extended-release (XL) bupropion hydrochloride (HCl) received FDA approval for Major Depressive Disorder (MDD) in 2003 and for Seasonal Affective Disorder (SAD) in 2006. XL bupropion hydrobromide (HBr)…
Bydureon™, the Exenatide extended-release formulation depot, has been approved in the USA for once weekly treatment for type 2 diabetes mellitus. Exenatide is a synthetic version of exendin
their side effects. The goal of this work is to develop an extended-release formulation, able to maintain the activity effect against the cholesterol, obtaining a constant release of statins
their side effects. The goal of this work is to develop an extended-release formulation that able to maintain the activity effect against cholesterol, obtaining a constant release of statins
other opioids are currently available in the USA, at present there is no extended-release hydromorphone product on the market. With regard to OROS hydromorphone, a candidate to fill this
patients with ischemic heart disease and chronic angina in January 2006, ranolazine extended-release is the latest addition to the armamentarium of antianginal medications. Although the exact mechanism of action
intramuscular option is currently available in fast-acting form while the long-acting (extended-release, depot) formulation was just approved by the US FDA. The purpose of this article
mania and in the maintenance phase, and as monotherapy in bipolar depression. The extended-release preparation with once-daily dosing may potentially enhance adherence. Studies of this formulation reveal
novel formulation of extended-release (ER) methylphenidate hydrochloride that utlizes multiple layers of coatings on microbeads for encapsulation into hard gelatin capsule shells (AptensioâÂ?¢, MPH-MLR) was evaluated to…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.